Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2015

View Archived Issues

Vitae Pharmaceuticals gives details on discovery of LXRbeta agonist

First inhalable prostacyclin IP receptor agonist for pulmonary arterial hypertension

Astellas Pharma begins phase Ib/II study of ASP-2215 in combination with erlotinib

FDA grants fast track designation to CF-301

R-Pharm acquires Ixempra from Bristol-Myers Squibb

Cadila Healthcare patents kappa-opioid receptor agonists

GlaxoSmithKline reports development of LRRK2 inhibitors

Roche describes HBsAg secretion inhibitors

AVEO forms license agreement with Novartis for AV-380 and related antibodies

CSIR scientists develop agents for treatment of tuberculosis

Ono Pharmaceutical synthesizes GABA(A) receptor alpha5 subunit NAMs

Health Canada approves Strensiq for hypophosphatasia

Phase II trial of oral CR-845 begins in osteoarthritis

Phase Ib modified diet trial achieves primary objective in Duchenne muscular dystrophy

European Commission grants marketing authorization to Unituxin

A novel modified glycosaminoglycan shows efficacy for mouth disorders

SymBio updates on clinical trials of rigosertib and azacitidine in MDS and AML

Spectrum Pharmaceuticals gains FDA agreement on requirements for apaziquone NDA filing

Pfenex wins BARDA contract to develop anthrax vaccine

FDA accepts NDA filing for octreotide

FDA accepts NDA for dronabinol oral solution for CINV- and AIDS-associated anorexia

Retrotope starts recruitment in phase I/II trial of RT-001 in Friedreich's ataxia

AstraZeneca positions antitumor compound AZD-4320 for clinical development

FDA approves Procysbi for children aged 2-6 years with nephropathic cystinosis

Novel alpha7 nACh receptor partial agonist shows potential for use in schizophrenia

Kite Pharma's KTE-C19 reports on phase I portion of NHL trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...